

**RECEIVED**  
**CENTRAL FAX CENTER**  
**JUL 27 2005**

ABX-PF1 DIV2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Ilia I. Ouspenski  
Group Art Unit : 1644  
Applicants : Douglas Charles Hanson et al.  
Application No. : 10/776,649  
Confirmation No. : 5045  
Filed : February 10, 2004  
For : HUMAN MONOCLONAL ANTIBODIES TO CTLA-4

New York, New York  
July 27, 2005

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

TRANSMITTAL LETTER FOR  
INFORMATION DISCLOSURE STATEMENT


Sir:

Transmitted herewith is an Information Disclosure Statement in the above-identified application.

This Statement is submitted more than three months from the application filing date, but before the mailing of the first Office Action on the merits. In accordance with 37 C.F.R. § 1.97 (b)(3), no fee is due in connection with this Statement. However, if for any reason a fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit

Account No. 06-1075, Order No. 000659-0030. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,



Jane T. Gunnison (Reg. No. 38,479)

Attorney for Applicants

R. Minako Pazdera (Reg. No. 46,984)

Agent for Applicants

c/o FISH & NEAVE IP GROUP

ROPES & GRAY LLP

Customer No. 1473

1251 Avenue of the Americas

New York, New York 10020-1105

Tel.: (212) 596-9000

Fax.: (212) 596-9090

RECEIVED  
CENTRAL FAX CENTER  
JUL 27 2005

ABX-PF1 DIV2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Ilia I. Ouspenski  
Group Art Unit : 1644  
Applicants : Douglas Charles Hanson et al.  
Application No. : 10/776,649  
Confirmation No. : 5045  
Filed : February 10, 2004  
For : HUMAN MONOCLONAL ANTIBODIES TO CTLA-4

New York, New York  
July 27, 2005

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

TRANSMITTAL LETTER FOR  
INFORMATION DISCLOSURE STATEMENT


Sir:

Transmitted herewith is an Information Disclosure Statement in the above-identified application.

This Statement is submitted more than three months from the application filing date, but before the mailing of the first Office Action on the merits. In accordance with 37 C.F.R. § 1.97 (b)(3), no fee is due in connection with this Statement. However, if for any reason a fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this Information Disclosure Statement to Deposit

Account No. 06-1075, Order No. 000659-0030. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,



Jane T. Gundison (Reg. No. 38,479)

Attorney for Applicants

R. Minako Pazdera (Reg. No. 46,984)

Agent for Applicants

c/o FISH & NEAVE IP GROUP

ROPES & GRAY LLP

Customer No. 1473

1251 Avenue of the Americas

New York, New York 10020-1105

Tel.: (212) 596-9000

Fax.: (212) 596-9090

**RECEIVED**  
**CENTRAL FAX CENTER**  
**JUL 27 2005**

ABX-PF1 DIV.:

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Examiner : Ilia I. Ouspenski  
Group Art Unit : 1644  
Applicants : Douglas Charles Hanson et al.  
Application No. : 10/776,649  
Confirmation No. : 5045  
Filed : February 10, 2004  
For : HUMAN MONOCLONAL ANTIBODIES TO CTLA-4

New York, New York  
July 27, 2005

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §§ 1.56 AND 1.97**

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants make of record the following documents<sup>1</sup>:

---

<sup>1</sup> For the Examiner's convenience, applicants have also enclosed a completed Form PTO/SB/08A, listing these documents.

UNITED STATES PATENT DOCUMENT

<u>Inventor</u>	<u>Patent No.</u>	<u>Issue Date</u>
Rhodes	Re 35,500	May 6, 1997
Lonberg et al.	6,255,458	July 3, 2001
Kuchroo et al.	6,207,156	March 27, 2001
Kucherlapati et al.	6,162,963	December 19, 2000
Kucherlapati et al.	6,150,584	November 21, 2002
Kucherlapati et al.	6,114,598	September 5, 2000
Kucherlapati et al.	6,075,181	June 13, 2000
Allison et al.	6,051,227	April 18, 2000
Linsley et al.	5,977,318	November 2, 1999
Linsley et al.	5,968,510	October 19, 1999
Kucherlapati et al.	5,939,598	August 17, 1999
Hori et al.	5,916,771	June 29, 1999
Allison et al.	5,855,887	January 5, 1999
Meade et al.	5,827,690	October 27, 1998
Lonberg et al.	5,814,318	September 29, 1998
Allison et al.	5,811,097	September 22, 1998
Lonberg et al.	5,789,650	August 4, 1998
Berns et al.	5,789,215	August 4, 1998
Co et al.	5,777,085	July 7, 1998
Linsley et al.	5,773,253	June 30, 1998
Lonberg et al.	5,770,429	June 23, 1998
Linsley et al.	5,770,197	June 23, 1998
Denman et al.	5,756,687	May 26, 1998
Meade et al.	5,750,172	May 12, 1998
Deboer et al.	5,741,957	April 21, 1998
Johnson et al.	5,733,743	March 31, 1998
Kay et al.	5,721,367	February 24, 1998
Co et al.	5,714,350	February 3, 1998
Johnston et al.	5,703,057	December 30, 1997
Goldenberg	5,697,902	December 16, 1997
Torii et al.	5,693,792	December 2, 1997
Queen et al.	5,693,761	December 2, 1997
Lonberg et al.	5,661,016	August 26, 1997
Buttram et al.	5,648,471	July 15, 1997
Dunn et al.	5,643,763	July 1, 1997
Lonberg et al.	5,633,425	May 27, 1997
Lonberg et al.	5,625,126	April 29, 1997
Kay et al.	5,612,205	March 18, 1997
Krimpenfort et al.	5,591,669	January 7, 1997
Queen et al.	5,585,089	December 17, 1996

Lonberg et al.	5,569,825	October 29, 1996
Surani et al.	5,545,807	August 13, 1996
Lonberg et al.	5,545,806	August 13, 1996
Queen et al.	5,530,101	June 25, 1996
Linsley et al.	5,434,131	July 18, 1995
Khawli et al.	5,194,594	March 16, 1993
Stec et al.	5,151,510	September 29, 1992
Rhodes	5,102,990	April 7, 1992
Goldenberg	5,101,827	April 7, 1992
Clark et al.	4,959,455	September 25, 1990
Kaufman et al.	4,912,040	March 27, 1990
Boss et al.	4,816,397	March 28, 1989
Kaufman	4,740,461	April 26, 1988
Goldenberg	4,735,210	April 5, 1988
Mullis	4,683,202	July 28, 1987
Mullis et al.	4,683,195	July 28, 1987
Coates	4,681,581	July 21, 1987
Axel et al.	4,399,216	August 16, 1983
Korman et al.	2002/0086014	July 4, 2002

FOREIGN PATENT DOCUMENTS

<u>Publication No.</u>	<u>Publication Date</u>
CA 2,205,680	November 16, 1998
EP 0 546 073	June 16, 1993
EP 0 463 151	January 2, 1992
EP 0 338 841	October 25, 1989
EP 0 323 997	July 19, 1989
EP 0 256 055	February 24, 1988
EP 0 239 400	August 3, 1994
EP 0 216 846	April 8, 1987
WO 01/14424	March 1, 2001
WO 00/32231	June 8, 2000
WO 98/50433	November 12, 1998
WO 98/46996	October 22, 1998
WO 98/42752	October 1, 1998
WO 98/24893	June 11, 1998
WO 98/24884	June 11, 1998
WO 97/38137	October 16, 1997
WO 97/20574	June 12, 1997
WO 97/13852	April 17, 1997
WO 96/34096	October 31, 1996
WO 96/33735	October 31, 1996
WO 96/22380	July 25, 1996
WO 96/14436	May 17, 1996
WO 95/33770	December 14, 1995
WO 95/24217	September 14, 1995
WO 95/03408	February 2, 1995
WO 95/01994	January 19, 1995
WO 94/29444	December 22, 1994
WO 94/25585	November 10, 1994
WO 94/02602	February 3, 1994
WO 94/00569	January 6, 1994
WO 93/12227	June 24, 1993
WO 93/00431	January 7, 1993
WO 92/22670	December 23, 1992
WO 92/22647	December 23, 1992
WO 92/22645	December 23, 1992
WO 92/03918	March 19, 1992
WO 91/10741	July 25, 1991



### OTHER DOCUMENTS

Alegre et al., "Regulation of surface and intracellular expression of CTLA4 on mouse T cells," *J. Immunol.*, 157:4762-4770 (1996)

Allison & Krummel, "The Yin and Yang of T cell costimulation," *Science*, 270:932-933 (1995)

Balzano et al., "CTLA-4 and CD28: Similar proteins, neighbouring genes," *Int. J. Cancer: Supplement*, 7:28-32 (1992)

Barker and Dayhoff, "Detecting distant relationships: computer methods and results," *Atlas of Protein Sequence and Structure*, pp. 101-110 (Volume 5, National Biomedical Research Foundation (1972)

Blair et al., "Cutting edge: CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X<sub>L</sub> induction," *J Immunol*, 160:12-15 (1998)

Blake and Litzi-Davis, "Evaluation of peptide libraries: An iterative strategy to analyze the reactivity of peptide mixtures with antibodies," *Bioconjugate Chem.*, 3:510-513 (1992)

Boussiotis et al., "Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation," *Proc Natl Acad Sci USA*, 90:11059-11063 (1993)

Bowie et al., "A method to identify protein sequences that fold into a known three-dimensional structure," *Science*, 253:164-170 (1991)

Bruggemann et al., "A repertoire of monoclonal antibodies with human heavy chains from transgenic mice," *PNAS USA*, 86:6709-6713 (1989)

Bruggemann and Neuberger, "Generation of antibody repertoires in transgenic mice," *Methods: A companion to Methods in Enzymology*, 2:159-165 (1991)

Bruggemann et al., "Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus," *Eur. J. Immunol.*, 21:1323-1326 (1991)

Bruggemann and Neuberger, "Strategies for expressing human antibody repertoires in transgenic mice," *Immunology Today*, 17:391-397 (1996)

Brunet et al., "A new member of the immunoglobulin superfamily - CTLA-4," *Nature*, 328:267-270 (1987)

Bumpers et al., "Consistent hepatic metastasis of human colorectal cancer in severe combined immunodeficient mice," *J. Surgical Res.*, 61:282-288 (1996)

Castan et al., "Accumulation of CTLA-4 expressing T lymphocytes in the germinal centres of human lymphoid tissues," *Immunology*, 90:265-271 (1997)

Chen et al., "Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules Cd28 and CTLA-4," *Cell*, 71:1093-1102 (1992)

Chen et al. "Immunoglobulin gene rearrangement in B-cell deficient mice generated by targeted deletion of the J<sub>H</sub> locus," *International Immunology*, 5:647-656 (1993)

Chen et al., "Intracellular antibodies as a new class of therapeutic molecules for gene therapy," *Human Gene Therapy*, 5:595-601 (1994)

Chiswell and McCafferty, "Phage antibodies: will new 'coliclonal' antibodies replace monoclonal antibodies?" *TIBTECH*, 10:80-84 (1992)

Choi et al., "Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome," *Nature Genetics*, 4:117-123 (1993)

Chothia & Lesk, "Canonical structures for the hypervariable regions of immunoglobulins," *J. Mol. Biol.*, 196:901-917 (1987)

Chothia et al., "Conformations of immunoglobulin hypervariable regions," *Nature*, 342:877-883 (1989)

Chuang et al., "Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression," *J. Immunol.*, 159:144-151 (1997)

Coligan et al., "Unit 2.1, "Enzyme-linked immunosorbent assays," *Current Protocols in Immunology*, 2.1.1-2.1.22 (1994)

Cwirla et al., "Peptides on phage: a vast library of peptides for identifying ligands," *PNAS USA*, 87:6378-6382 (1990)

Dariavach et al., "Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains," *Eur. J. Immunol.*, 18:1901-1905 (1988)

Dayhoff, "Survey of new data and computer methods of analysis," *Atlas of Protein Sequence and Structure*, pp. 1-10 (Volume 5, Supplement 2, National Biomedical Research Foundation (1976))

de Boer et al., "Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells," *Eur J Immunol*, 23:3120-3125 (1993)

Evans et al., "Design of nonpeptidal ligands for a peptide receptor: cholecystokinin antagonists," *J. Med. Chem.*, 30:1229-1239 (1987)

Fallarino et al., "B7-1 Engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28," *J Exp Med*, 188:205-210 (1998)

Fanger et al., "Production and use of anti-FcR bispecific antibodies," *ImmunoMethods*, 4:72-81 (1994)

Fauchere, "Elements for the rational design of peptide drugs," *Adv. Drug Res.*, 15:29-69 (1986)

Fishwild et al., "High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice," *Nature Biotech.*, 14:845-851 (1996)

Foster et al., "Molecular Mechanisms and Selective Influences That Shape the Kappa Gene Repertoire of IgM<sup>+</sup> B Cells," *J. Clin. Invest.*, 99, No. 7:1614-1627 (1997)

Freeman et al., "Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production," *J Exp Med.*, 178:2185-2192 (1993)

Freeman et al., "Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice," *Science*, 262:907-909 (1993)

Freeman et al., "The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor," *J Immunol*, 161:2708-2715 (1998)

Fry et al., "Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor," *Proc Nat'l Acad Sci USA*, 95:12022-12027 (1998)

Furet et al., "Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411," *Journal of Computer-Aided Molecular Design*, 9:465-472 (1995)

Galfre and Milstein, "Preparation of monoclonal antibodies: strategies and procedures." *Methods Enzymol.*, 73:3-46 (1981)

Ginalski et al., "Modelling of active forms of protein kinases: p38 - a case study," *Acta Biochimica Polonica*, 44:557-564 (1997)

Gorman et al., "The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection," *Proc Nat'l Acad Sci USA*, 79:6777-6781 (1982)

Green and Jakobovits, "Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes," *J. Exp. Med.*, 188:483-495 (1998)

Green et al., "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs," *Nature Genetics*, 7:13-21 (1994)

Gribben et al., "CTLA4 mediates antigen-specific apoptosis of human T cells," *Proc. Natl. Acad. Sci.*, 92:811-815 (1995)

Grosschedl and Baltimore, "Cell-type specificity of immunoglobulin gene expression is regulated by at least three DNA sequence elements," *Cell*, 41:885-897(1985)

Hanes and Plückthun, "In vitro selection and evolution of functional proteins by using ribosome display," *Proc Nat'l Acad Sci USA*, 94:4937-4942 (1997)

Harding et al., "CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones," *Nature*, 356:607-609 (1992)

Harper et al., "CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location," *J Immunol*, 147:1037-1044 (1991)

Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," *Science*, 262:905-907 (1993)

Hofmann et al., "A model of Cdc25 phosphatase catalytic Domain and Cdk-interaction surface based on the presence of a rhodanese homology domain," *J Mol Biol*, 282:195-208 (1998)

Holliger et al., "'Diabodies': Small bivalent and bispecific antibody fragments," *PNAS USA* 90:6444-6448 (1993)

Hoogenboom et al., "Building antibodies from their genes," *Immunol. Reviews*, 130:43-68 (1992)

Horspool et al., "Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4," *J Immunol*, 160:2706-2714 (1998)

Houghten et al., "The use of synthetic peptide combinatorial libraries for the identification of bioactive peptides," *BioTechniques*, 13:412-421 (1992)

Houghten, "General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids," *Proc Nat'l Acad Sci USA*, 82:5131-5135 (1985)

Hurwitz et al., "Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis," *J Neuroimmunol*, 73:57-62 (1997)

Hurwitz et al., "CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma," *Proc Natl Acad Sci USA*, 95:10067-10071 (1998)

Ill et al., "Design and construction of a hybrid immunoglobulin domain with properties of both heavy and light chain variable regions," *Protein Engineering*, 10:949-957 (1997)

Jakobovits et al., "Germ-line transmission and expression of a human-derived yeast artificial-chromosome." *Nature*, 362:255-258 (1993)

Jakobovits et al., "Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production." *Proc. Natl. Acad. Sci. USA*, 90:2551-2555 (1993)

Jakobovits, "Humanizing the mouse genome." *Current Biology*, 4:761-763 (1994)

Jakobovits, "Production of fully human antibodies by transgenic mice." *Current Opinion in Biotechnology*, 6:561-566 (1995)

Jakobovits, "The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice," *Expert Opinion on Investigational Drugs*, 7:607-614 (1998)

Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," *Nature*, 321:522-525 (1986).

Joukov et al., "Identification of Csk tyrosine phosphorylation sites and a tyrosine residue important for kinase domain structure," *Biochem J*, 322:927-935 (1997)

Junghans et al. in *Cancer Chemotherapy and Biotherapy*, 655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996))

Kostelny et al., "Formation of a bispecific antibody by the use of leucine zippers," *J. Immunol.*, 148:1547-1553 (1992)

Krummel and Allison, "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation," *J Exp Med*, 182:459-465 (1995)

Krummel et al., "Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo," *Int Immunol*, 8:519-523 (1996)

- Kuchroo et al., "B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy," *Cell*, 80:707-718 (1995)
- Kwon et al., "Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer," *Proc Nat'l Acad Sci USA*, 94:8099-80103 (1997)
- LaPlanche et al., "Phosphorothioate-modified oligodeoxyribonucleotides. III NMR and UV spectroscopic studies of the R<sub>p</sub>-R<sub>p</sub>, S<sub>p</sub>-S<sub>p</sub> duplexes. [d(GG<sub>s</sub> AATTCC)]<sub>2</sub>, derived from diastereomeric O-ethyl phosphorothioates," *Nucl. Acids Res.*, 14:9081-9093 (1986)
- Lenschow et al., "Expression and functional significance of an additional ligand for CTLA-4," *Proc Nat'l Acad Sci USA*, 90:11054-11058 (1993)
- Lenschow et al., "Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg," *Science*, 257:789-792 (1992)
- "Leucocyte Typing VI: White Cell Differentiation Antigens," *Garland Publishing*, New York, NY, pp 30-31, 95-98 and 1213-1214
- Lin et al., "Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28," *J Exp Med*, 188:199-204 (1998)
- Linsley et al., "CTLA-4 is a second receptor for the B cell activation antigen B7," *J. Exp. Med.*, 174:561-569 (1991)
- Linsley et al., "Coexpression and functional cooperation of CTLA-4 and CD-28 on activated T lymphocytes," *J Exp Med*, 176:1595-1604 (1992)
- Linsley et al., "Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule," *Science*, 257:792-795 (1992)
- Liu et al., "Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity," *J.Immunol.*, 139:3521-3526 (1987)
- Liu et al., "Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells," *Proc Nat'l Acad Sci USA*, 84:3439-3443 (1987)
- Lonberg et al., "Antigen-specific human antibodies from mice comprising four distinct genetic modifications," *Nature*, 368:856-859 (1994)
- Luhder et al., "Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes," *J Exp Med*, 187:427-432 (1998)

- Mandal et al., "ABGEN: A knowledge-based automated approach for antibody structure modeling," *Nature Biotechnology*, 14:323-328 (1996)
- Marasco, "Intrabodies: turning the humoral immune system outside in for intracellular immunization," *Gene Therapy*, 4:11-15 (1997)
- Markees et al., "Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4," *J Clin Invest*, 101:2446-2455 (1998)
- Marks et al., "Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes." *Eur. J. Immunol.*, 21:985-991 (1991)
- Marrack et al., "The Staphylococcal Enterotoxins and Their Relatives," *Science*, 705-711 (1990)
- Martin et al., "The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6," *The EMBO Journal*, 13:5303-5309 (1994)
- McCoy et al., "Protective immunity to nematode infection is induced by CTLA-4 blockade," *J Exp Med*, 186:183-187 (1997)
- Mendez et al., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice," *Nature Genetics*, 15:146-156 (1997)
- Monfardini et al. "Rational design, analysis, and potential utility of GM-CSF antagonists," *Proc Assoc Am Physicians*, 108:420-431 (1996)
- Morrison, "Transfectomas provide novel chimeric antibodies," *Science*, 229:1202-1207 (1985).
- Murphy et al., "Blockade of CTLA-4 enhances host resistance to the intercellular pathogen, *Leishmania donovani*," *J. Immunol.*, 161:4153-4160 (1998)
- Needleman and Wunsch, "A general method applicable to the search for similarities in the amino acid sequence to two proteins," *Mol. Biol.*, 48:443-453 (1970)
- Neuberger et al., "A hapten-specific chimaeric IgE antibody with human physiological effector function," *Nature*, 314:268-270 (1985).
- Oi et al., "Chimeric antibodies," *Biotechniques*, 4(3):214-221 (1986).
- Okayama et al., "A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells," *Mol. Cell. Bio.*, 3:280-289 (1983).

- O'Kennedy et al., "Antibody engineering: an overview," *Essays in Biochemistry*, 46:59-75 (1991).
- Parmley and Smith, "Antibody-selectable filamentous fd phage vectors: affinity purification of target genes," *Gene*, 73:305-318 (1988)
- Parren, "Preparation of genetically engineered monoclonal antibodies for human immunotherapy," *Human Antibodies and Hybridomas*, 3:137-145 (1992).
- Pearson and Lipman, "Improved tools for biological sequence comparison," *Proc. Natl. Acad. Sci. U.S.A.*, 85:2444-2448 (1988)
- Perez et al., "Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement," *Immunity*, 6:411-417 (1997)
- Perrin et al., "B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis," *Immunol Res*, 14:189-199 (1995)
- Perrin et al. "CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis" *J Immunol*, 157:1333-1336 (1996)
- Pinilla et al., "Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries," *Biotechniques*, 13:901-905 (1992)
- Powell et al., "Compendium of excipients for parenteral formulations," *PDA J Pharm Sci Technol*. 52:238-311 (1998)
- Razi-Wolf et al., "Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor," *Proc Natl Acad Sci USA*, 90:11182-11186 (1993)
- Riechmann et al., "Reshaping human antibodies for therapy," *Nature*, 332:323-327 (1988).
- Rizo and Gierasch, "Constrained peptides: models of bioactive peptides and protein substructures," *Annu. Rev. Biochem.*, 61:387-418 (1992)
- Russel et al., "Retroviral vectors displaying functional antibody fragments," *Nucl. Acids Research*, 21:1081-1085 (1993)
- Schwartz, "Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy," *Cell*, 71:1065-1068 (1992)
- Scott, "Discovering peptide ligands using epitope libraries," *Trends in Biochemical Sciences*, 17:241-245 (1992)



- Singh et al., "Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases," *J Med Chem*, 40:1130-1135 (1997)
- Smith and Waterman, "Comparison of Biosequences," *Adv. Appl. Math.*, 2:482-489 (1981)
- Songsivilai and Lachmann, "Bispecific antibody: a tool for diagnosis and treatment of disease," *Clin. Exp. Immunol.*, 79: 315-321 (1990)
- Stec et al., "Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides," *J. Am. Chem. Soc.*, 106:6077-6079 (1984)
- Stein et al., "Physicochemical properties of phosphorothioate oligodeoxynucleotides," *Nucl. Acids Res.*, 16:3209-3221 (1988)
- Taylor et al., "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins," *Nucleic Acids Research*, 20:6287-6295 (1992)
- Taylor et al., "Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM," *International Immunology*, 6:579-591 (1994)
- Thornton et al., "Prediction of progress at last" *Nature*, 354:105-106 (1991)
- Tivol et al., "Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4," *Immunity*, 3:541-547 (1995)
- Townsend and Allison, "Tumor rejection after direct costimulation of CD8<sup>+</sup> T cells by B7-transfected melanoma cells," *Science*, 259:368-370 (1993)
- Traunecker et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells," *EMBO J*, 10:3655-3659 (1991)
- Traunecker et al., "Janusin: new molecular design for bispecific reagents," *Int. J. Cancer (Suppl.)*, 7:51-52 (1992)
- Tuaillon et al., "Analysis of direct and inverted DJ<sub>H</sub> rearrangements in a human Ig heavy chain transgenic minilocus," *J. Immunol.*, 154:6453-6465 (1995)
- Tuaillon et al., "Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: gene-segment use in  $\mu$  and  $\gamma$  transcripts," *Proc. Natl. Acad. Sci. USA*, 90:3720-3724 (1993)
- Uhlmann and Peyman, "Antisense RNA: A natural gene expression control system," *Chemical Reviews*, 90:543-584 (1990)

- Van Parijs et al., "Role of interleukin 12 and costimulators in T cell anergy in vivo," *The Journal of Experimental Medicine*, 186, 1119-1128 (1997)
- Vaswani et al., "Humanized antibodies as potential therapeutic drugs," *Annals of Allergy, Asthma & Immunology*, 81:105-119 (1998).
- Veber and Freidinger, "The design of metabolically-stable peptide analogs," *Trends In Neuro Sciences*, pp. 392-396 (1985)
- Verhoeyen et al., "Reshaping human antibodies: grafting an antilysozyme activity," *Science*, 239:1534-1536 (1988).
- Vitetta et al., "Immunotoxins: magic bullets or misguided missiles," *Immunol Today*, 14:252-259 (1993)
- Walunas et al., "CTLA-4 can function as a negative regulator of T cell activation," *Immunity*, 1:405-413 (1994)
- Walunas et al., "CTLA-4 ligation blocks CD28-dependent T cell activation," *J Exp Med*, 183:2541-2550 (1996)
- Waterhouse et al., "Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4," *Science*, 270:985-988 (1995)
- Winter and Harris, "Humanized Antibodies," *Immunol Today*, 14:243-246 (1993)
- Wright et al., "Genetically engineered antibodies: Progress and prospects," *Crit. Reviews in Immunol.*, 12:125-168 (1992)
- Wu, "From esoteric theory to therapeutic antibodies," *Applied Biochemistry and Biotechnology*, 47(2/3):107-118 (1994).
- Yang et al., "Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages," *Cancer Res*, 57:4036-4041 (1997)
- Yi-qun et al., "Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens," *Int Immunol*, 8:37-44 (1996)
- Zon et al., "Phosphorothioate oligonucleotides: chemistry, purification, analysis, scale-up and future directions," *Anti-Cancer Drug Design*, 6:539-568 (1991)

Zon et al., "Phosphorothioate oligonucleotides," Oligonucleotides and Analogues: A Practical Approach, pp. 87-108 (F. Eckstein, Ed., Oxford University Press, Oxford England (1991))

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if known</b>	
				Application Number	10/776,649
Sheet 1		of 18		Filing Date	February 10, 2004
				First Named Inventor	Hanson
				Art Unit	1644
				Examiner Name	Ilija I. Ouspenski
				Attorney Docket Number	ABX-PF1 DIV2

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Documents	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
		RE 35,500	05/16/1997	Rhodes	
		6,255,458	07/03/2001	Lonberg et al.	
		6,207,156	03/27/2001	Kuchroo et al.	
		6,162,963	12/19/2000	Kucherlapati et al.	
		6,150,584	11/21/2002	Kucherlapati et al.	
		6,114,598	09/05/2000	Kucherlapati et al.	
		6,075,181	06/13/2000	Kucherlapati et al.	
		6,051,227	04/18/2000	Allison et al.	
		5,977,318	11/02/1999	Linsley et al.	
		5,968,510	10/19/1999	Linsley et al.	
		5,939,598	08/17/1999	Kucherlapati et al.	
		5,916,771	06/29/1999	Hori et al.	
		5,855,887	01/05/1999	Allison et al.	
		5,827,690	10/27/1998	Meade et al.	
		5,814,318	09/29/1998	Lonberg et al.	
		5,811,097	09/22/1998	Allison et al.	
		5,789,650	08/04/1998	Lonberg et al.	
		5,789,215	08/04/1998	Berns et al.	
		5,777,085	07/07/1998	Co et al.	
		5,773,253	06/30/1998	Linsley et al.	
		5,770,429	06/23/1998	Lonberg et al.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if known</b>	
				Application Number	10/776,649
Sheet 2		of 18		Filing Date	February 10, 2004
				First Named Inventor	Hanson
				Art Unit	1644
				Examiner Name	Ilia I. Ouspenski
				Attorney Docket Number	ABX-PF1 DIV2

U.S. PATENT DOCUMENTS					
		5,770,197	06/23/1998	Linsley et al.	
		5,756,687	05/26/1998	Denman et al.	
		5,750,172	05/12/1998	Meade et al.	
		5,741,957	04/21/1998	Deboer et al.	
		5,733,743	03/31/1998	Johnson et al.	
		5,721,367	02/24/1998	Kay et al.	
		5,714,350	02/03/1998	Co et al.	
		5,703,057	12/30/1997	Johnston et al.	
		5,697,902	12/16/1997	Godenberg	
		5,693,792	12/02/1997	Torii et al.	
		5,693,761	12/02/1997	Queen et al.	
		5,661,016	08/26/1997	Lonberg et al.	
		5,648,471	07/15/1997	Buttram et al.	
		5,643,763	07/01/1997	Dunn et al.	
		5,633,425	05/27/1997	Lonberg et al.	
		5,625,126	04/29/1997	Lonberg et al.	
		5,612,205	03/18/1997	Kay et al.	
		5,591,669	01/07/1997	Krimpenfort et al.	
		5,585,089	12/17/1996	Queen et al.	
		5,569,825	10/29/1996	Lonberg et al.	
		5,545,807	08/13/1996	Surani et al.	
		5,545,806	08/13/1996	Lonberg et al.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if known</b>	
				Application Number	10/776,649
				Filing Date	February 10, 2004
				First Named Inventor	Hanson
				Art Unit	1644
				Examiner Name	Ilia I. Ouspenski
				Attorney Docket Number	ABX-PF1 DIV2
Sheet	3	of	18		

U.S. PATENT DOCUMENTS					
		5,530,101	06/25/1996	Queen et al.	
		5,434,131	07/18/1995	Linsley et al.	
		5,194,594	03/16/1993	Khawli et al.	
		5,151,510	09/29/1992	Stec et al.	
		5,102,990	04/07/1992	Rhodes	
		5,101,827	04/07/1992	Goldenberg	
		4,959,455	09/25/1990	Clark et al.	
		4,912,040	03/27/1990	Kaufman et al.	
		4,816,397	03/28/1989	Boss et al.	
		4,740,461	04/26/1988	Kaufman	
		4,735,210	04/05/1988	Goldenberg	
		4,683,202	07/28/1987	Mullis	
		4,683,195	07/28/1982	Mullis et al.	
		4,681,581	07/21/1987	Coates	
		4,399,216	08/16/1983	Axel et al.	
		2002/0086014	07/04/2002	Korman et al.	

FOREIGN PATENT DOCUMENTS						
Examiner initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Country	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>2</sup> - Number <sup>3</sup> - Kind Code <sup>5</sup>				
		CA 2,205,680	11/16/1998	Canada		
		EP 0 546 073	06/16/1993	Europe		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not drawn is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (10-01,

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if known</b>	
				Application Number	10/776,649
				Filing Date	February 10, 2004
				First Named Inventor	Hanson
				Art Unit	1644
				Examiner Name	Ilia I. Ouspenski
				Attorney Docket Number	ABX-PF1 DIV2
Sheet	4	of	18		

FOREIGN PATENT DOCUMENTS						
		EP 0 463 151	01/02/1992	Europe		
		EP 0 338 841	10/25/1989	Europe		
		EP 0 323 997	07/19/1989	Europe		
		EP 0 256 055	02/24/1998	Europe		
		EP 0 239 400	08/03/1994	Europe		
		EP 0 216 846	04/08/1987	Europe		
		WO 01/14424	03/01/2001	PCT		
		WO 00/32231	06/08/2000	PCT		
		WO 98/50433	11/12/1998	PCT		
		WO 98/46996	10/22/1998	PCT		
		WO 98/42752	10/01/1998	PCT		
		WO 98/24893	06/11/1998	PCT		
		WO 98/24884	06/11/1998	PCT		
		WO 97/38137	10/16/1997	PCT		
		WO 97/20574	06/12/1997	PCT		
		WO 97/13852	04/17/1997	PCT		
		WO 96/34096	10/31/1996	PCT		
		WO 96/33735	10/31/1996	PCT		
		WO 96/22380	07/25/1996	PCT		
		WO 96/14436	05/17/1996	PCT		
		WO 95/33770	12/14/1995	PCT		
		WO 95/24217	09/14/1995	PCT		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if known</b>	
		<b>Application Number</b>	10/776,649
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Filing Date</b>	February 10, 2004
		<b>First Named Inventor</b>	Hanson
(use as many sheets as necessary)		<b>Art Unit</b>	1644
		<b>Examiner Name</b>	Ilia I. Ouspenski
<b>Sheet</b>	5	<b>of</b>	18
		<b>Attorney Docket Number</b>	ABX-PF1 DIV2

FOREIGN PATENT DOCUMENTS					
		WO 95/03408	02/02/1995	PCT	
		WO 95/01994	01/19/1995	PCT	
		WO 94/29444	12/22/1994	PCT	
		WO 94/25585	11/10/1994	PCT	
		WO 94/02602	02/03/1994	PCT	
		WO 94/00569	01/06/1994	PCT	
		WO 93/12227	06/24/1993	PCT	
		WO 93/00431	01/07/1993	PCT	
		WO 92/22670	12/23/1992	PCT	
		WO 92/22647	12/23/1992	PCT	
		WO 92/22645	12/23/1992	PCT	
		WO 92/03918	03/19/1992	PCT	
		WO 91/10741	07/25/1991	PCT	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published	T*
		Alegre et al., "Regulation of surface and intracellular expression of CTLA4 on mouse T cells," <i>J. Immunol.</i> , 157:4762-4770 (1996)	
		Allison & Krummel, "The Yin and Yang of T cell costimulation," <i>Science</i> , 270:932-933 (1995)	
		Balzano et al., "CTLA-4 and CD28: Similar proteins, neighbouring genes," <i>Int. J. Cancer: Supplement</i> , 7:28-32 (1992)	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/776,649
		Filing Date	February 10, 2004
		First Named Inventor	Hanson
		Art Unit	1644
		Examiner Name	Ilia I. Ouspenski
		Attorney Docket Number	ABX-PF1 DIV2
Sheet	6	of	18

NON PATENT LITERATURE DOCUMENTS		
	Barker and Dayhoff, "Detecting distant relationships: computer methods and results," <i>Atlas of Protein Sequence and Structure</i> , pp. 101-110 (Volume 5, National Biomedical Research Foundation (1972)	
	Blair et al., "Cutting edge: CTLA-4 ligation delivers a unique signal to resting human CD4 T cells that inhibits interleukin-2 secretion but allows Bcl-X <sub>L</sub> induction," <i>J Immunol</i> , 160:12-15 (1998)	
	Blake and Litz-Davis, "Evaluation of peptide libraries: An iterative strategy to analyze the reactivity of peptide mixtures with antibodies," <i>Bioconjugate Chem.</i> , 3:510-513 (1992)	
	Boussiotis et al., "Activated human B lymphocytes express three CTLA-4 counterreceptors that costimulate T-cell activation," <i>Proc Natl Acad Sci USA</i> , 90:11059-11063 (1993)	
	Bowie et al., "A method to identify protein sequences that fold into a known three-dimensional structure," <i>Science</i> , 253:164-170 (1991)	
	Bruggemann et al., "A repertoire of monoclonal antibodies with human heavy chains from transgenic mice," <i>PNAS USA</i> , 86:6709-6713 (1989)	
	Bruggemann and Neuberger, "Generation of antibody repertoires in transgenic mice," <i>Methods: A companion to Methods in Enzymology</i> , 2:159-165 (1991)	
	Bruggemann et al., "Human antibody production in transgenic mice: expression from 100 kb of the human IgH locus," <i>Eur. J. Immunol.</i> , 21:1323-1326 (1991)	
	Bruggemann and Neuberger, "Strategies for expressing human antibody repertoires in transgenic mice," <i>Immunology Today</i> , 17:391-397 (1996)	
	Brunet et al., "A new member of the immunoglobulin superfamily - CTLA-4," <i>Nature</i> , 328:267-270 (1987)	
	Bumpers et al., "Consistent hepatic metastasis of human colorectal cancer in severe combined immunodeficient mice," <i>J. Surgical Res.</i> , 61:282-288 (1996)	
	Castan et al., "Accumulation of CTLA-4 expressing T lymphocytes in the germinal centres of human lymphoid tissues," <i>Immunology</i> , 90:265-271 (1997)	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if known</b>	
				Application Number	10/776,649
				Filing Date	February 10, 2004
				First Named Inventor	Hanson
				Art Unit	1644
				Examiner Name	Iliia I. Ouspenski
				Attorney Docket Number	ABX-PF1 DIV2
Sheet	7	of	18		

NON PATENT LITERATURE DOCUMENTS		
	Chen et al., "Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules Cd28 and CTLA-4," <i>Cell</i> , 71:1093-1102 (1992)	
	Chen et al. "Immunoglobulin gene rearrangement in B-cell deficient mice generated by targeted deletion of the J <sub>H</sub> locus," <i>International Immunology</i> , 5:647-656 (1993)	
	Chen et al., "Intracellular antibodies as a new class of therapeutic molecules for gene therapy," <i>Human Gene Therapy</i> , 5:595-601 (1994)	
	Chiswell and McCafferty, "Phage antibodies: will new 'coliclonal' antibodies replace monoclonal antibodies?" <i>TIBTECH</i> , 10:80-84 (1992)	
	Choi et al., "Transgenic mice containing a human heavy chain immunoglobulin gene fragment cloned in a yeast artificial chromosome," <i>Nature Genetics</i> , 4:117-123 (1993)	
	Chothia & Lesk, "Canonical structures for the hypervariable regions of immunoglobulins," <i>J. Mol. Biol.</i> , 196:901-917 (1987)	
	Chothia et al., "Conformations of immunoglobulin hypervariable regions," <i>Nature</i> , 342:877-883 (1989)	
	Chuang et al., "Interaction of CTLA-4 with the clathrin-associated protein AP50 results in ligand-independent endocytosis that limits cell surface expression," <i>J. Immunol.</i> , 159:144-151 (1997)	
	Coligan et al., "Unit 2.1, "Enzyme-linked immunosorbent assays," <i>Current Protocols in Immunology</i> , 2.1.1-2.1.22 (1994)	
	Cwirla et al., "Peptides on phage: a vast library of peptides for identifying ligands," <i>PNAS USA</i> , 87:6378-6382 (1990)	
	Dariavach et al., "Human Ig superfamily CTLA-4 gene: chromosomal localization and identity of protein sequence between murine and human CTLA-4 cytoplasmic domains," <i>Eur. J. Immunol.</i> , 18:1901-1905 (1988)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if known</b>	
				Application Number	10/776,649
				Filing Date	February 10, 2004
				First Named Inventor	Hanson
				Art Unit	1644
				Examiner Name	Ilia I. Ouspenski
				Attorney Docket Number	ABX-PF1 DIV2
Sheet	8	of	18		

NON PATENT LITERATURE DOCUMENTS		
		Dayhoff, "Survey of new data and computer methods of analysis," <i>Atlas of Protein Sequence and Structure</i> , pp. 1-10 (Volume 5, Supplement 2, National Biomedical Research Foundation (1976))
		de Boer et al., "Ligation of B7 with CD28/CTLA-4 on T cells results in CD40 ligand expression, interleukin-4 secretion and efficient help for antibody production by B cells," <i>Eur J Immunol</i> , 23:3120-3125 (1993)
		Evans et al., "Design of nonpeptidic ligands for a peptide receptor: cholecystokinin antagonists," <i>J. Med. Chem.</i> , 30:1229-1239 (1987)
		Fallarino et al., "B7-1 Engagement of cytotoxic T lymphocyte antigen 4 inhibits T cell activation in the absence of CD28," <i>J Exp Med</i> , 188:205-210 (1998)
		Fanger et al., "Production and use of anti-FcR bispecific antibodies," <i>ImmunoMethods</i> , 4:72-81 (1994)
		Fauchere, "Elements for the rational design of peptide drugs," <i>Adv. Drug Res.</i> , 15:29-69 (1986)
		Fishwild et al., "High-avidity human IgGκ monoclonal antibodies from a novel strain of minilocus transgenic mice," <i>Nature Biotech.</i> , 14:845-851 (1996)
		Foster et al., "Molecular Mechanisms and Selective Influences That Shape the Kappa Gene Repertoire of IgM <sup>+</sup> B Cells," <i>J. Clin. Invest.</i> , 99, No. 7:1614-1627 (1997)
		Freeman et al., "Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production," <i>J Exp Med.</i> , 178:2185-2192 (1993)
		Freeman et al., "Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice," <i>Science</i> , 262:907-909 (1993)
		Freeman et al., "The BB1 monoclonal antibody recognizes both cell surface CD74 (MHC class II-associated invariant chain) as well as B7-1 (CD80), resolving the question regarding a third CD28/CTLA-4 counterreceptor," <i>J Immunol</i> , 161:2708-2715 (1998)

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Application Number</b>	10/776,649
		<b>Filing Date</b>	February 10, 2004
		<b>First Named Inventor</b>	Hanson
		<b>Art Unit</b>	1644
		<b>Examiner Name</b>	Ilia I. Ouspenski
		<b>Attorney Docket Number</b>	ABX-PF1 DIV2
<b>Sheet</b>	9	<b>of</b>	18

NON PATENT LITERATURE DOCUMENTS		
	Fry et al., "Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor," <i>Proc Nat'l Acad Sci USA</i> , 95:12022-12027 (1998)	
	Furer et al., "Modelling study of protein kinase inhibitors: binding mode of staurosporine and origin of the selectivity of CGP 52411," <i>Journal of Computer-Aided Molecular Design</i> , 9:465-472 (1995)	
	Galfre and Milstein, "Preparation of monoclonal antibodies: strategies and procedures," <i>Methods Enzymol.</i> , 73:3-46 (1981)	
	Ginalski et al., "Modelling of active forms of protein kinases: p38 - a case study," <i>Acta Biochimica Polonica</i> , 44:557-564 (1997)	
	Gorman et al., "The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection," <i>Proc Nat'l Acad Sci USA</i> , 79:6777-6781 (1982)	
	Green and Jakobovits, "Regulation of B cell development by variable gene complexity in mice reconstituted with human immunoglobulin yeast artificial chromosomes," <i>J. Exp. Med.</i> , 188:483-495 (1998)	
	Green et al., "Antigen-specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs," <i>Nature Genetics</i> , 7:13-21 (1994)	
	Gribben et al., "CTLA4 mediates antigen-specific apoptosis of human T cells," <i>Proc. Natl. Acad. Sci.</i> , 92:811-815 (1995)	
	Grosschedl and Baltimore, "Cell-type specificity of immunoglobulin gene expression is regulated by at least three DNA sequence elements," <i>Cell</i> , 41:885-897(1985)	
	Hanes and Plückthun, "In vitro selection and evolution of functional proteins by using ribosome display," <i>Proc Nat'l Acad Sci USA</i> , 94:4937-4942 (1997)	
	Harding et al., "CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones," <i>Nature</i> , 356:607-609 (1992)	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office Unit issued the document, by the two-letter code (NISO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO.				<b>Complete if known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/776,649
				Filing Date	February 10, 2004
				First Named Inventor	Hanson
				Art Unit	1644
				Examiner Name	Iliia I. Ouspenski
Sheet	10	of	18	Attorney Docket Number	ABX-PF1 DIV2

NON PATENT LITERATURE DOCUMENTS		
	Harper et al., "CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location," <i>J Immunol</i> , 147:1037-1044 (1991)	
	Hathcock et al., "Identification of an alternative CTLA-4 ligand costimulatory for T cell activation," <i>Science</i> , 262:905-907 (1993)	
	Hofmann et al., "A model of Cdc25 phosphatase catalytic Domain and Cdk-interaction surface based on the presence of a rhodanese homology domain," <i>J Mol Biol</i> , 282:195-208 (1998)	
	Holliger et al., "'Diabodies': Small bivalent and bispecific antibody fragments," <i>PNAS USA</i> 90:6444-6448 (1993)	
	Hoogenboom et al., "Building antibodies from their genes," <i>Immunol. Reviews</i> , 130:43-68 (1992)	
	Horspool et al., "Nucleic acid vaccine-induced immune responses require CD28 costimulation and are regulated by CTLA4," <i>J Immunol</i> , 160:2706-2714 (1998)	
	Houghten et al., "The use of synthetic peptide combinatorial libraries for the identification of bioactive peptides," <i>BioTechniques</i> , 13:412-421 (1992)	
	Houghten, "General method for the rapid solid-phase synthesis of large numbers of peptides: Specificity of antigen-antibody interaction at the level of individual amino acids," <i>Proc Nat'l Acad Sci USA</i> , 82:5131-5135 (1985)	
	Hurwitz et al., "Specific blockade of CTLA-4/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis," <i>J Neuroimmunol</i> , 73:57-62 (1997)	
	Hurwitz et al., "CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma," <i>Proc Natl Acad Sci USA</i> , 95:10067-10071 (1998)	
	Ill et al., "Design and construction of a hybrid immunoglobulin domain with properties of both heavy and light chain variable regions," <i>Protein Engineering</i> , 10:949-957 (1997)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if known</b>	
		<b>Application Number</b>	10/776,649
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Filing Date</b>	February 10, 2004
		<b>First Named Inventor</b>	Hanson
		<b>Art Unit</b>	1644
		<b>Examiner Name</b>	Iliia I. Ouspenski
(use as many sheets as necessary)		<b>Attorney Docket Number</b>	ABX-PF1 DIV2
Sheet	11	of	18

NON PATENT LITERATURE DOCUMENTS	
	Jakobovits et al., "Germ-line transmission and expression of a human-derived yeast artificial-chromosome." <i>Nature</i> , 362:255-258 (1993)
	Jakobovits et al., "Analysis of homozygous mutant chimeric mice: Deletion of the immunoglobulin heavy-chain joining region blocks B-cell development and antibody production." <i>Proc. Natl. Acad. Sci. USA</i> , 90:2551-2555 (1993)
	Jakobovits, "Humanizing the mouse genome." <i>Current Biology</i> , 4:761-763 (1994)
	Jakobovits, "Production of fully human antibodies by transgenic mice." <i>Current Opinion in Biotechnology</i> , 6:561-566 (1995)
	Jakobovits, "The long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice," <i>Expert Opinion on Investigational Drugs</i> , 7:607-614 (1998)
	Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse," <i>Nature</i> , 321:522-525 (1986).
	Joukov et al., "Identification of Csk tyrosine phosphorylation sites and a tyrosine residue important for kinase domain structure," <i>Biochem J</i> , 322:927-935 (1997)
	Junghans et al. in <i>Cancer Chemotherapy and Biotherapy</i> , 655-686 (2d edition, Chafner and Longo, eds., Lippincott Raven (1996))
	Kostelny et al., "Formation of a bispecific antibody by the use of leucine zippers," <i>J. Immunol.</i> , 148:1547-1553 (1992)
	Krummel and Allison, "CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation," <i>J Exp Med</i> , 182:459-465 (1995)
	Krummel et al., "Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo," <i>Int Immunol</i> , 8:519-523 (1996)

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. 6 Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/776,649
				Filing Date	February 10, 2004
				First Named Inventor	Hanson
				Art Unit	1644
				Examiner Name	Iliia I. Ouspenski
Sheet	12	of	18	Attorney Docket Number	ABX-PF1 DIV2

NON PATENT LITERATURE DOCUMENTS		
		Kuchroo et al., "B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy," <i>Cell</i> , 80:707-718 (1995)
		Kwon et al., "Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer," <i>Proc Nat'l Acad Sci USA</i> , 94:8099-80103 (1997)
		LaPlanche et al., "Phosphorothioate-modified oligodeoxyribonucleotides. III NMR and UV spectroscopic studies of the R <sub>p</sub> -R <sub>p</sub> , S <sub>p</sub> -S <sub>p</sub> duplexes. [d(GG <sub>8</sub> AATCC)] <sub>2</sub> derived from diastereomeric O-ethyl phosphorothioates," <i>Nucl. Acids Res.</i> , 14:9081-9093 (1986)
		Lenschow et al., "Expression and functional significance of an additional ligand for CTLA-4," <i>Proc Nat'l Acad Sci USA</i> , 90:11054-11058 (1993)
		Lenschow et al., "Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg," <i>Science</i> , 257:789-792 (1992)
		"Leucocyte Typing VI: White Cell Differentiation Antigens," <i>Garland Publishing</i> , New York, NY, pp 30-31, 95-98 and 1213-1214
		Lin et al., "Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28," <i>J Exp Med</i> , 188:199-204 (1998)
		Linsley et al., "CTLA-4 is a second receptor for the B cell activation antigen B7," <i>J. Exp. Med.</i> , 174:561-569 (1991)
		Linsley et al., "Coexpression and functional cooperation of CTLA-4 and CD-28 on activated T lymphocytes," <i>J Exp Med</i> , 176:1595-1604 (1992)
		Linsley et al., "Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule," <i>Science</i> , 257:792-795 (1992)
		Liu et al., "Production of a mouse-human chimeric monoclonal antibody to CD20 with potent Fc-dependent biologic activity," <i>J.Immunol.</i> , 139:3521-3526 (1987)

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if known</b>	
		Application Number	10/776,649
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		Filing Date	February 10, 2004
		First Named Inventor	Hanson
		Art Unit	1644
		Examiner Name	Iliia I. Ouspenski
(use as many sheets as necessary)		Attorney Docket Number	ABX-PF1 DIV2
Sheet	13	of	18

NON PATENT LITERATURE DOCUMENTS		
	Liu et al., "Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells," <i>Proc Nat'l Acad Sci USA</i> , 84:3439-3443 (1987)	
	Lonberg et al., "Antigen-specific human antibodies from mice comprising four distinct genetic modifications," <i>Nature</i> , 368:856-859 (1994)	
	Luhder et al., "Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes," <i>J Exp Med</i> , 187:427-432 (1998)	
	Mandal et al., "ABGEN: A knowledge-based automated approach for antibody structure modeling," <i>Nature Biotechnology</i> , 14:323-328 (1996)	
	Marasco, "Intrabodies: turning the humoral immune system outside in for intracellular immunization," <i>Gene Therapy</i> , 4:11-15 (1997)	
	Markees et al., "Long-term survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferon-gamma, and CTLA4," <i>J Clin Invest</i> , 101:2446-2455 (1998)	
	Marks et al., "Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes," <i>Eur. J. Immunol.</i> , 21:985-991 (1991)	
	Marrack et al., "The Staphylococcal Enterotoxins and Their Relatives," <i>Science</i> , 705-711 (1990)	
	Martin et al., "The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6," <i>The EMBO Journal</i> , 13:5303-5309 (1994)	
	McCoy et al., "Protective immunity to nematode infection is induced by CTLA-4 blockade," <i>J Exp Med</i> , 186:183-187 (1997)	
	Mendez et al., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice," <i>Nature Genetics</i> , 15:146-156 (1997)	
	Monfardini et al. "Rational design, analysis, and potential utility of GM-CSF antagonists," <i>Proc Assoc Am Physicians</i> , 108:420-431 (1996)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Document. at www.USPTO.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



PTO/SB/08A (1D-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if known</b>	
		<b>Application Number</b>	10/776,649
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Filing Date</b>	February 10, 2004
		<b>First Named Inventor</b>	Hanson
(use as many sheets as necessary)		<b>Art Unit</b>	1644
		<b>Examiner Name</b>	Iliia I. Ouspenski
<b>Sheet</b>	14	<b>of</b>	18
		<b>Attorney Docket Number</b>	ABX-PF1 DIV2

NON PATENT LITERATURE DOCUMENTS		
	Morrison, "Transfectomas provide novel chimeric antibodies," <i>Science</i> , 229:1202-1207 (1985).	
	Murphy et al., "Blockade of CTLA-4 enhances host resistance to the intercellular pathogen, <i>Leishmania donovani</i> ," <i>J. Immunol.</i> , 161:4153-4160 (1998)	
	Needleman and Wunsch, "A general method applicable to the search for similarities in the amino acid sequence to two proteins," <i>Mol. Biol.</i> , 48:443-453 (1970)	
	Neuberger et al., "A hapten-specific chimaeric IgE antibody with human physiological effector function," <i>Nature</i> , 314:268-270 (1985).	
	Oi et al., "Chimeric antibodies," <i>Biotechniques</i> , 4(3):214-221 (1986).	
	Okayama et al., "A cDNA cloning vector that permits expression of cDNA inserts in mammalian cells," <i>Mol. Cell. Bio.</i> , 3:280-289 (1983).	
	O'Kennedy et al., "Antibody engineering: an overview," <i>Essays in Biochemistry</i> , 46:59-75 (1991).	
	Parnley and Smith, "Antibody-selectable filamentous fd phage vectors: affinity purification of target genes," <i>Gene</i> , 73:305-318 (1988)	
	Parren, "Preparation of genetically engineered monoclonal antibodies for human immunotherapy," <i>Human Antibodies and Hybridomas</i> , 3:137-145 (1992).	
	Pearson and Lipman, "Improved tools for biological sequence comparison," <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 85:2444-2448 (1988)	
	Perez et al., "Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement," <i>Immunity</i> , 6:411-417 (1997)	
	Perrin et al., "B7-mediated costimulation can either provoke or prevent clinical manifestations of experimental allergic encephalomyelitis," <i>Immunol Res</i> , 14:189-199 (1995)	

<b>Examiner Signature</b>	<b>Date Considered</b>
-------------------------------	----------------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Index Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete If Known</b>	
		<b>Application Number</b>	10/776,649
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Filing Date</b>	February 10, 2004
		<b>First Named Inventor</b>	Hanson
(use as many sheets as necessary)		<b>Art Unit</b>	1644
		<b>Examiner Name</b>	Ilija I. Ouspenski
<b>Sheet</b>	15	<b>of</b>	18
		<b>Attorney Docket Number</b>	ABX-PF1 DIV2

NON PATENT LITERATURE DOCUMENTS		
	Perrin et al. "CTLA-4 blockade enhances clinical disease and cytokine production during experimental allergic encephalomyelitis" <i>J Immunol</i> , 157:1333-1336 (1996)	
	Pinilla et al., "Rapid identification of high affinity peptide ligands using positional scanning synthetic peptide combinatorial libraries," <i>Biotechniques</i> , 13:901-905 (1992)	
	Powell et al., "Compendium of excipients for parenteral formulations," <i>PDA J Pharm Sci Technol.</i> 52:238-311 (1998)	
	Razi-Wolf et al., "Evidence for an additional ligand, distinct from B7, for the CTLA-4 receptor," <i>Proc Natl Acad Sci USA</i> , 90:11182-11186 (1993)	
	Riechmann et al., "Reshaping human antibodies for therapy," <i>Nature</i> , 332:323-327 (1988).	
	Rizo and Gierasch, "Constrained peptides: models of bioactive peptides and protein substructures," <i>Annu. Rev. Biochem.</i> , 61:387-418 (1992)	
	Russel et al., "Retroviral vectors displaying functional antibody fragments," <i>Nucl. Acids Research</i> , 21:1081-1085 (1993)	
	Schwartz, "Costimulation of T lymphocytes: The role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy," <i>Cell</i> , 71:1065-1068 (1992)	
	Scott, "Discovering peptide ligands using epitope libraries," <i>Trends in Biochemical Sciences</i> , 17:241-245 (1992)	
	Singh et al., "Structure-based design of a potent, selective, and irreversible inhibitor of the catalytic domain of the erbB receptor subfamily of protein tyrosine kinases," <i>J Med Chem</i> , 40:1130-1135 (1997)	
	Smith and Waterman, "Comparison of Biosequences," <i>Adv. Appl. Math.</i> , 2:482-489 (1981)	
	Songsivilai and Lachmann, "Bispecific antibody: a tool for diagnosis and treatment of disease," <i>Clin. Exp. Immunol.</i> , 79: 315-321 (1990)	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.15 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if known</b>	
		<b>Application Number</b>	10/776,649
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Filing Date</b>	February 10, 2004
		<b>First Named Inventor</b>	Hanson
		<b>Art Unit</b>	1644
		<b>Examiner Name</b>	Ilija I. Ouspenski
		<b>Attorney Docket Number</b>	ABX-PF1 DIV2
<b>Sheet</b>	16	<b>of</b>	18

NON PATENT LITERATURE DOCUMENTS		
	Stec et al., "Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogues of oligodeoxyribonucleotides," <i>J. Am. Chem. Soc.</i> , 106:6077-6079 (1984)	
	Stein et al., "Physicochemical properties of phosphorothioate oligodeoxynucleotides," <i>Nucl. Acids Res.</i> , 16:3209-3221 (1988)	
	Taylor et al., "A transgenic mouse that expresses a diversity of human sequence heavy and light chain immunoglobulins," <i>Nucleic Acids Research</i> , 20:6287-6295 (1992)	
	Taylor et al., "Human immunoglobulin transgenes undergo rearrangement, somatic mutation and class switching in mice that lack endogenous IgM," <i>International Immunology</i> , 6:579-591 (1994)	
	Thornton et al., "Prediction of progress at last" <i>Nature</i> , 354:105-106 (1991)	
	Tivol et al., "Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4," <i>Immunity</i> , 3:541-547 (1995)	
	Townsend and Allison, "Tumor rejection after direct costimulation of CD8 <sup>+</sup> T cells by B7-transfected melanoma cells," <i>Science</i> , 259:368-370 (1993)	
	Traunecker et al., "Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells," <i>EMBO J.</i> , 10:3655-3659 (1991)	
	Traunecker et al., "Janusin: new molecular design for bispecific reagents," <i>Int. J. Cancer (Suppl.)</i> , 7:51-52 (1992)	
	Tuaillon et al., "Analysis of direct and inverted DJ <sub>H</sub> rearrangements in a human Ig heavy chain transgenic minilocus," <i>J. Immunol.</i> , 154:6453-6465 (1995)	
	Tuaillon et al., "Human immunoglobulin heavy-chain minilocus recombination in transgenic mice: gene-segment use in $\mu$ and $\gamma$ transcripts," <i>Proc. Natl. Acad. Sci. USA</i> , 90:3720-3724 (1993)	
	Uhlmann and Peyman, "Antisense RNA: A natural gene expression control system," <i>Chemical Reviews</i> , 90:543-584 (1990)	

<b>Examiner Signature</b>		<b>Date Considered</b>	
---------------------------	--	------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if known</b>	
		<b>Application Number</b>	10/776,649
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		<b>Filing Date</b>	February 10, 2004
		<b>First Named Inventor</b>	Hanson
(use as many sheets as necessary)		<b>Art Unit</b>	1644
		<b>Examiner Name</b>	Illa I. Ouspenski
<b>Sheet</b>	17	<b>of</b>	18
		<b>Attorney Docket Number</b>	ABX-PF1 DIV2

NON PATENT LITERATURE DOCUMENTS		
	Van Parijs et al., "Role of interleukin 12 and costimulators in T cell anergy in vivo," <i>The Journal of Experimental Medicine</i> , 186, 1119-1128 (1997)	
	Vaswani et al., "Humanized antibodies as potential therapeutic drugs," <i>Annals of Allergy, Asthma &amp; Immunology</i> , 81:105-119 (1998).	
	Veber and Freidinger, "The design of metabolically-stable peptide analogs," <i>Trends In Neuro Sciences</i> , pp. 392-396 (1985)	
	Verhoeven et al., "Reshaping human antibodies: grafting an antilysozyme activity," <i>Science</i> , 239:1534-1536 (1988).	
	Vitetta et al., "Immunotoxins: magic bullets or misguided missiles," <i>Immunol Today</i> , 14:252-259 (1993)	
	Walunas et al., "CTLA-4 can function as a negative regulator of T cell activation," <i>Immunity</i> , 1:405-413 (1994)	
	Walunas et al., "CTLA-4 ligation blocks CD28-dependent T cell activation," <i>J Exp Med</i> , 183:2541-2550 (1996)	
	Waterhouse et al., "Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4," <i>Science</i> , 270:985-988 (1995)	
	Winter and Harris, "Humanized Antibodies," <i>Immunol Today</i> , 14:243-246 (1993)	
	Wright et al., "Genetically engineered antibodies: Progress and prospects," <i>Crit. Reviews in Immunol.</i> , 12:125-168 (1992)	
	Wu, "From esoteric theory to therapeutic antibodies," <i>Applied Biochemistry and Biotechnology</i> , 47(2/3):107-118 (1994).	
	Yang et al., "Enhanced induction of antitumor T-cell responses by cytotoxic T lymphocyte-associated molecule-4 blockade: The effect is manifested only at the restricted tumor-bearing stages," <i>Cancer Res</i> , 57:4036-4041 (1997)	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not consider it. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner

PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1985, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	10/776,649
				Filing Date	February 10, 2004
				First Named Inventor	Hanson
				Art Unit	1644
				Examiner Name	Iliia I. Ouspenski
Sheet	18	of	18	Attorney Docket Number	ABX-PF1 DIV2

NON PATENT LITERATURE DOCUMENTS			
		Yi-qun et al., "Differential requirements for co-stimulatory signals from B7 family members by resting versus recently activated memory T cells towards soluble recall antigens," <i>Int Immunol</i> , 8:37-44 (1996)	
		Zon et al., "Phosphorothioate oligonucleotides: chemistry, purification, analysis, scale-up and future directions," <i>Anti-Cancer Drug Design</i> , 6:539-568 (1991)	
		Zon et al., "Phosphorothioate oligonucleotides," <i>Oligonucleotides and Analogues: A Practical Approach</i> , pp. 87-108 (F. Eckstein, Ed., Oxford University Press, Oxford England (1991))	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450.